Pew Responds to White House's Drug Pricing Blueprint Information Request

Comments address administration’s questions on how federal, manufacturer programs affect spending

The White House's Drug Pricing Blueprint

The Pew Charitable Trusts sent a letter July 16 to the U.S. Department of Health and Human Services, offering comments on the Trump administration’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs Request for Information (RFI).

Pew’s response to the RFI addresses the following topics:

  • Federal program incentives.
  • Drug pricing structures and incentives.
  • Proposals to reform the Medicare Part B Competitive Acquisition Program.
  • Price reporting requirements and incentive structures.
  • Cost-shifting and cross-subsidization.
  • Generic drug pricing and development.
  • Pharmacy benefit managers and rebates.
  • 340B Drug Pricing Program.
  • Patient cost-sharing.

National Homeownership Month

Article

37 Researchers Working to Transform Biomedical Science

Quick View
Article

Biomedical researchers are on the front lines of scientific innovation. From responding to global pandemics to pioneering lifesaving cancer treatments, these researchers push past scientific boundaries to solve pressing health challenges. For nearly 40 years, The Pew Charitable Trusts has supported more than 1,000 early-career biomedical scientists committed to this discovery.

Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.